セファロスポリン医薬品の世界市場レポート 2025年

セファロスポリン医薬品の市場規模は、今後数年間で安定した成長が見込まれます。2029年には206億4,000万米ドルに成長し、CAGRは4.4%となります。予測期間に予測される成長は、高齢者人口の拡大、細菌感染に対する意識の高まり、入院患者の増加、新しいセファロスポリン製剤の継続的な開発に起因しています。この期間に予想される主な動向としては、製剤技術の革新、製造における先端技術の統合、新規セファロスポリン誘導体の台頭、ドラッグデリバリーシステムの進歩などが挙げられます。

感染症の増加は、今後数年間のセファロスポリン医薬品市場の拡大を牽引すると予測されます。感染症は、細菌、ウイルス、真菌、寄生虫などの微生物によって引き起こされる病気で、人から人へ感染する可能性があります。このような感染症の増加は、主に抗菌薬耐性の問題が拡大していることに起因しており、以前は対処可能であった感染症が治療困難となり、その結果、より持続的で広範な疾病が発生します。セファロスポリン医薬品は、幅広い抗菌特性を持つため、さまざまな細菌病原体に対して有効であり、こうした感染症の治療に役立っています。セファロスポリン医薬品は、迅速かつ効果的な治療により治療期間を短縮し、患者の回復を促進します。例えば、2023年11月、米国保健社会福祉省は、2022年に新たに記録された慢性B型肝炎患者が前年比11％増加したと報告しました。その結果、感染症の罹患率の上昇がセファロスポリン医薬品市場の成長に寄与しています。

セファロスポリン医薬品市場の主要企業は、抗菌薬耐性と闘い、薬剤耐性感染症の世界的な増加に対処するため、グラム陰性菌感染症を対象とした治療など、先進的な治療オプションの創出に注力しています。グラム陰性菌感染症の治療には、従来の抗生物質に対する耐性を本質的に高めている、独特の細胞壁構造を持つ細菌を標的とする特殊な抗生物質の使用が必要です。例えば、2024年5月、Shionogi & Co. Ltd.は、グラム陰性菌感染症の治療薬として、特殊な抗生物質を使用することを発表しました。日本の製薬会社であるShionogi & Co. Ltd.は2024年5月、薬剤耐性株を含む重度のグラム陰性菌感染症に対処するために開発された新しい抗生物質、フェトロージャ（セフィデロクール）を発表しました。その革新的なトロイの木馬戦略により、複数の耐性メカニズムを迂回することが可能となり、代替薬が限られている患者に重要な治療選択肢を提供します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のセファロスポリン医薬品のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のセファロスポリン医薬品市場：成長率分析
• 世界のセファロスポリン医薬品市場の実績：規模と成長、2019～2024年
• 世界のセファロスポリン医薬品市場の予測：規模と成長、2024～2029年、2034年
• 世界のセファロスポリン医薬品総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のセファロスポリン医薬品市場：世代別、実績と予測、2019～2024年、2024～2029年、2034年
• 第一世代
• 第二世代
• 第三世代
• 第四世代
• 第五世代
• 世界のセファロスポリン医薬品市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 非経口
• 局所
• 世界のセファロスポリン医薬品市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 皮膚感染症
• 呼吸器感染症
• 尿路感染症
• 性感染症
• 耳の感染症
• その他
• 世界のセファロスポリン医薬品市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のセファロスポリン医薬品市場：第一世代のサブセグメンテーション：世代別、実績と予測、2019～2024年、2024～2029年、2034年
• セファゾリン
• セフラジン
• セファレキシン
• 世界のセファロスポリン医薬品市場：第二世代のサブセグメンテーション：世代別、実績と予測、2019～2024年、2024～2029年、2034年
• セフロキシム
• ロラカルベフ
• セファクロル
• セフプロジル
• 世界のセファロスポリン医薬品市場：第三世代のサブセグメンテーション、世代別、実績と予測、2019～2024年、2024～2029年、2034年
• セフトリアキソン
• セフジニル
• セフォタキシム
• セフタジジム
• 世界のセファロスポリン医薬品市場：第四世代のサブセグメンテーション：世代別、実績と予測、2019～2024年、2024～2029年、2034年
• セフェピム
• セフピロム
• 世界のセファロスポリン医薬品市場：第五世代のサブセグメンテーション：世代別、実績と予測、2019～2024年、2024～2029年、2034年
• セフタロリン
• セフトビプロール

第7章 地域別・国別分析

• 世界のセファロスポリン医薬品市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のセファロスポリン医薬品市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• セファロスポリン医薬品市場：競合情勢
• セファロスポリン医薬品市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Abbott Laboratories
• Novartis AG
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Baxter International
• Macleods Pharmaceuticals Ltd
• Sun Pharmaceutical Industries Ltd.
• Lupin Limited
• Zydus Lifesciences Limited
• Alkem Laboratories Ltd.
• Mankind Pharma Limited
• Aristo Pharmaceuticals Ltd
• Hetero Drugs Ltd
• Covalent Laboratories Private Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• セファロスポリン医薬品市場2029年：新たな機会を提供する国
• セファロスポリン医薬品市場2029年：新たな機会を提供するセグメント
• セファロスポリン医薬品市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Cephalosporin drugs belong to the beta (B)-lactam class of antibiotics and are used to combat bacterial infections by disrupting the synthesis of the bacterial cell wall, resulting in cell death. These broad-spectrum antibiotics are categorized into generations based on their range of antimicrobial activity. Cephalosporins are frequently prescribed for various infections, including those of the respiratory tract, skin, urinary tract, and central nervous system, such as meningitis.

The cephalosporin drug generations include the first, second, third, fourth, and fifth generations. First-generation cephalosporins are mainly effective against gram-positive bacteria like streptococcus and staphylococcus species, with limited efficacy against gram-negative organisms. They can be administered orally, via injection, or topically. Their clinical uses encompass the treatment of skin, respiratory, urinary tract, sexually transmitted, and ear infections, among others. These medications are available through hospital pharmacies, retail drugstores, and online platforms.

The cephalosporin drugs market research report is one of a series of new reports from The Business Research Company that provides cephalosporin drugs market statistics, including the cephalosporin drugs industry's global market size, regional shares, competitors with the cephalosporin drugs market share, detailed cephalosporin drugs market segments, market trends and opportunities, and any further data you may need to thrive in the cephalosporin drugs market. This cephalosporin drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cephalosporin drugs market size has grown steadily in recent years. It will grow from $16.56 billion in 2024 to $17.34 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. Growth during the historical period can be credited to the rising prevalence of bacterial infections, the escalation of antibiotic resistance, increased healthcare spending, and the growing demand for generic medications.

The cephalosporin drugs market size is expected to see steady growth in the next few years. It will grow to $20.64 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. Growth projected for the forecast period can be attributed to the expanding elderly population, heightened awareness of bacterial infections, a rise in hospital admissions, and continued development of new cephalosporin formulations. Key trends anticipated during this period include innovations in drug formulation technologies, integration of advanced technology in manufacturing, the emergence of novel cephalosporin derivatives, and progress in drug delivery systems.

The increasing occurrence of infectious diseases is projected to drive the expansion of the cephalosporin drugs market in the coming years. Infectious diseases are illnesses triggered by microorganisms such as bacteria, viruses, fungi, or parasites, which can be transmitted from one person to another. This rise in infectious diseases is primarily attributed to the growing issue of antimicrobial resistance, which renders previously manageable infections more difficult to treat, resulting in more persistent and widespread illness. Cephalosporin drugs are instrumental in treating these infections due to their broad-spectrum antibacterial properties, making them effective against a wide range of bacterial pathogens. They help shorten treatment duration by delivering rapid and effective relief, thereby enhancing patient recovery. For example, in November 2023, the U.S. Department of Health and Human Services reported that newly documented chronic hepatitis B cases increased by 11% in 2022 compared to the previous year. Consequently, the rising incidence of infectious diseases is contributing to the growth of the cephalosporin drugs market.

Leading players in the cephalosporin drugs market are concentrating on creating advanced treatment options, such as those targeting gram-negative bacterial infections, to combat antimicrobial resistance and address the increasing global burden of drug-resistant infections. Treating gram-negative bacterial infections involves using specialized antibiotics to target bacteria that possess a distinct cell wall structure, which makes them inherently more resistant to conventional antibiotics. For instance, in May 2024, Shionogi & Co. Ltd., a pharmaceutical firm based in Japan, introduced FETROJA (Cefiderocol), a new antibiotic developed to combat severe gram-negative bacterial infections, including drug-resistant strains. Its innovative Trojan horse strategy enables it to bypass multiple resistance mechanisms, offering a vital therapeutic option for patients with limited alternatives.

In January 2024, Venatorx Pharmaceuticals Inc., a pharmaceutical company based in the U.S., formed a partnership with Menarini Group to secure exclusive rights for the commercialization of cefepime-taniborbactam across 96 countries. This collaboration is intended to enhance global availability of this next-generation antibiotic, designed to target multidrug-resistant bacterial infections. Menarini Group, headquartered in Italy, manufactures and develops cephalosporin-based drugs.

Major players in the cephalosporin drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., AstraZeneca plc, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Baxter International, Macleods Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd., Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Mankind Pharma Limited, Aristo Pharmaceuticals Ltd, Hetero Drugs Ltd, Covalent Laboratories Private Limited.

North America was the largest region in the cephalosporin drugs market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cephalosporin drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cephalosporin drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cephalosporin drugs market consists of sales of keflex, rocephin, and maxipime. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cephalosporin Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cephalosporin drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cephalosporin drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cephalosporin drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Generation: First Generation; Second Generation; Third Generation; Fourth Generation; Fifth Generation
• 2) By Route of Administration: Oral; Parenteral; Topical
• 3) By Application: Skin Infection; Respiratory Tract Infection; Urinary Tract Infection
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• Subsegments:
• 1) By First Generation: Cefazolin; Cephradine; Cephalexin
• 2) By Second Generation: Cefuroxime; Loracarbef; Cefaclor; Cefprozil
• 3) By Third Generation: Ceftriaxone; Cefdinir; Cefotaxime; Ceftazidime
• 4) By Fourth Generation: Cefepime; Cefpirome
• 5) By Fifth Generation: Ceftaroline; Ceftobiprole
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cephalosporin Drugs Market Characteristics

3. Cephalosporin Drugs Market Trends And Strategies

4. Cephalosporin Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Cephalosporin Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cephalosporin Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cephalosporin Drugs Market Growth Rate Analysis
• 5.4. Global Cephalosporin Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cephalosporin Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cephalosporin Drugs Total Addressable Market (TAM)

6. Cephalosporin Drugs Market Segmentation

• 6.1. Global Cephalosporin Drugs Market, Segmentation By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• First Generation
• Second Generation
• Third Generation
• Fourth Generation
• Fifth Generation
• 6.2. Global Cephalosporin Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Topical
• 6.3. Global Cephalosporin Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Skin Infection
• Respiratory Tract Infection
• Urinary Tract Infection
• Sexually Transmitted Infection
• Ear Infection
• Other Applications
• 6.4. Global Cephalosporin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.5. Global Cephalosporin Drugs Market, Sub-Segmentation Of First Generation, By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cefazolin
• Cephradine
• Cephalexin
• 6.6. Global Cephalosporin Drugs Market, Sub-Segmentation Of Second Generation, By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cefuroxime
• Loracarbef
• Cefaclor
• Cefprozil
• 6.7. Global Cephalosporin Drugs Market, Sub-Segmentation Of Third Generation, By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ceftriaxone
• Cefdinir
• Cefotaxime
• Ceftazidime
• 6.8. Global Cephalosporin Drugs Market, Sub-Segmentation Of Fourth Generation, By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cefepime
• Cefpirome
• 6.9. Global Cephalosporin Drugs Market, Sub-Segmentation Of Fifth Generation, By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ceftaroline
• Ceftobiprole

7. Cephalosporin Drugs Market Regional And Country Analysis

• 7.1. Global Cephalosporin Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cephalosporin Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cephalosporin Drugs Market

• 8.1. Asia-Pacific Cephalosporin Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cephalosporin Drugs Market, Segmentation By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cephalosporin Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cephalosporin Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cephalosporin Drugs Market

• 9.1. China Cephalosporin Drugs Market Overview
• 9.2. China Cephalosporin Drugs Market, Segmentation By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cephalosporin Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cephalosporin Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cephalosporin Drugs Market

• 10.1. India Cephalosporin Drugs Market, Segmentation By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cephalosporin Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cephalosporin Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cephalosporin Drugs Market

• 11.1. Japan Cephalosporin Drugs Market Overview
• 11.2. Japan Cephalosporin Drugs Market, Segmentation By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cephalosporin Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cephalosporin Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cephalosporin Drugs Market

• 12.1. Australia Cephalosporin Drugs Market, Segmentation By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cephalosporin Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cephalosporin Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cephalosporin Drugs Market

• 13.1. Indonesia Cephalosporin Drugs Market, Segmentation By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cephalosporin Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cephalosporin Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cephalosporin Drugs Market

• 14.1. South Korea Cephalosporin Drugs Market Overview
• 14.2. South Korea Cephalosporin Drugs Market, Segmentation By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cephalosporin Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cephalosporin Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cephalosporin Drugs Market

• 15.1. Western Europe Cephalosporin Drugs Market Overview
• 15.2. Western Europe Cephalosporin Drugs Market, Segmentation By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cephalosporin Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cephalosporin Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cephalosporin Drugs Market

• 16.1. UK Cephalosporin Drugs Market, Segmentation By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cephalosporin Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cephalosporin Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cephalosporin Drugs Market

• 17.1. Germany Cephalosporin Drugs Market, Segmentation By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cephalosporin Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cephalosporin Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cephalosporin Drugs Market

• 18.1. France Cephalosporin Drugs Market, Segmentation By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cephalosporin Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cephalosporin Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cephalosporin Drugs Market

• 19.1. Italy Cephalosporin Drugs Market, Segmentation By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cephalosporin Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cephalosporin Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cephalosporin Drugs Market

• 20.1. Spain Cephalosporin Drugs Market, Segmentation By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cephalosporin Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cephalosporin Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cephalosporin Drugs Market

• 21.1. Eastern Europe Cephalosporin Drugs Market Overview
• 21.2. Eastern Europe Cephalosporin Drugs Market, Segmentation By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cephalosporin Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cephalosporin Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cephalosporin Drugs Market

• 22.1. Russia Cephalosporin Drugs Market, Segmentation By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cephalosporin Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cephalosporin Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cephalosporin Drugs Market

• 23.1. North America Cephalosporin Drugs Market Overview
• 23.2. North America Cephalosporin Drugs Market, Segmentation By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cephalosporin Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cephalosporin Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cephalosporin Drugs Market

• 24.1. USA Cephalosporin Drugs Market Overview
• 24.2. USA Cephalosporin Drugs Market, Segmentation By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cephalosporin Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cephalosporin Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cephalosporin Drugs Market

• 25.1. Canada Cephalosporin Drugs Market Overview
• 25.2. Canada Cephalosporin Drugs Market, Segmentation By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cephalosporin Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cephalosporin Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cephalosporin Drugs Market

• 26.1. South America Cephalosporin Drugs Market Overview
• 26.2. South America Cephalosporin Drugs Market, Segmentation By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cephalosporin Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cephalosporin Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cephalosporin Drugs Market

• 27.1. Brazil Cephalosporin Drugs Market, Segmentation By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cephalosporin Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cephalosporin Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cephalosporin Drugs Market

• 28.1. Middle East Cephalosporin Drugs Market Overview
• 28.2. Middle East Cephalosporin Drugs Market, Segmentation By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cephalosporin Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cephalosporin Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cephalosporin Drugs Market

• 29.1. Africa Cephalosporin Drugs Market Overview
• 29.2. Africa Cephalosporin Drugs Market, Segmentation By Generation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cephalosporin Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cephalosporin Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cephalosporin Drugs Market Competitive Landscape And Company Profiles

• 30.1. Cephalosporin Drugs Market Competitive Landscape
• 30.2. Cephalosporin Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Cephalosporin Drugs Market Other Major And Innovative Companies

• 31.1. Abbott Laboratories
• 31.2. Novartis AG
• 31.3. Eli Lilly and Company
• 31.4. Teva Pharmaceutical Industries Ltd.
• 31.5. Astellas Pharma Inc.
• 31.6. Baxter International
• 31.7. Macleods Pharmaceuticals Ltd
• 31.8. Sun Pharmaceutical Industries Ltd.
• 31.9. Lupin Limited
• 31.10. Zydus Lifesciences Limited
• 31.11. Alkem Laboratories Ltd.
• 31.12. Mankind Pharma Limited
• 31.13. Aristo Pharmaceuticals Ltd
• 31.14. Hetero Drugs Ltd
• 31.15. Covalent Laboratories Private Limited

32. Global Cephalosporin Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cephalosporin Drugs Market

34. Recent Developments In The Cephalosporin Drugs Market

35. Cephalosporin Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Cephalosporin Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cephalosporin Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cephalosporin Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer